Meridian Bioscience (VIVO) stock price, revenue, and financials

Meridian Bioscience market cap is $741.3 m, and annual revenue was $201.01 m in FY 2019

$741.3 M

VIVO Mkt cap, 29-Sept-2020

$84.8 M

Meridian Bioscience Revenue Q3, 2020
Meridian Bioscience Gross profit (Q3, 2020)55.9 M
Meridian Bioscience Gross profit margin (Q3, 2020), %65.9%
Meridian Bioscience Net income (Q3, 2020)27.5 M
Meridian Bioscience EBIT (Q3, 2020)34.7 M
Meridian Bioscience Cash, 30-Jun-202063.4 M
Meridian Bioscience EV783.4 M

Meridian Bioscience Revenue

Meridian Bioscience revenue was $201.01 m in FY, 2019

Embed Graph

Meridian Bioscience Income Statement

Quarterly

USDQ3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

33.9m37.3m41.1m40.1m40.3m47.4m42.1m45.4m47.3m47.1m44.8m50.1m47.2m48.0m51.5m48.2m47.2m51.3m50.7m46.8m54.1m50.1m52.3m56.5m51.7m51.5m50.2m48.4m47.4m57.3m84.8m

Cost of goods sold

13.6m14.8m14.6m15.5m17.7m14.5m16.6m16.5m16.5m16.8m18.5m18.0m18.8m19.0m17.9m15.6m17.7m17.8m17.4m20.6m18.9m20.5m21.9m19.8m19.9m20.9m20.2m20.0m22.8m28.9m

Gross profit

23.6m26.3m25.4m24.7m29.8m27.6m28.8m30.7m30.6m28.0m31.6m29.2m29.2m32.5m30.3m31.6m33.6m32.9m29.5m33.5m31.2m31.8m34.6m32.0m31.6m29.3m28.3m27.4m34.5m55.9m

Gross profit Margin, %

63%64%63%61%63%66%63%65%65%63%63%62%61%63%63%67%65%65%63%62%62%61%61%62%61%58%58%58%60%66%

Sales and marketing expense

4.3m5.7m6.1m6.1m5.6m5.8m5.8m5.7m5.5m5.4m6.0m6.5m6.2m6.1m6.5m6.2m6.4m7.2m8.1m7.5m8.0m7.9m8.8m8.6m8.5m7.6m6.9m6.7m6.7m6.5m6.3m

R&D expense

2.1m2.3m2.4m2.7m2.3m2.5m2.7m2.5m2.8m2.7m2.9m3.2m3.1m3.1m3.4m3.2m3.4m3.1m3.5m3.4m3.9m3.9m4.5m4.2m4.3m4.0m3.8m4.6m4.8m5.4m6.7m

General and administrative expense

4.9m6.5m5.6m6.4m6.6m6.4m6.2m7.5m7.2m6.8m7.6m6.3m6.7m7.4m6.9m6.5m8.2m6.9m7.5m8.4m7.4m8.5m8.9m9.1m8.4m8.9m7.4m8.0m8.8m10.5m12.4m

Operating expense total

12.0m14.5m15.3m15.3m14.9m14.9m15.0m15.7m15.5m14.9m16.4m15.9m16.1m16.6m16.8m15.9m18.0m18.4m19.2m19.4m19.3m26.9m23.7m26.9m23.2m21.0m19.5m21.8m22.0m22.7m21.2m

EBIT

9.8m9.1m11.0m10.1m9.8m14.8m12.6m13.1m15.3m15.7m11.6m15.7m13.1m12.7m15.7m14.4m13.6m15.2m13.7m10.1m14.2m4.3m8.1m7.7m8.7m10.6m9.8m6.5m5.4m11.8m34.7m

EBIT margin, %

29%24%27%25%24%31%30%29%32%33%26%31%28%26%31%30%29%30%27%22%26%9%15%14%17%20%20%13%11%21%41%

Interest expense

20.0k220.0k145.0k62.0k321.0k35.0k45.0k135.0k276.0k148.0k216.0k22.0k252.0k576.0k205.0k93.0k113.0k364.0k340.0k426.0k4.0k358.0k403.0k454.0k115.0k75.0k588.0k14.0k1.4m

Interest income

29.0k17.0k27.0k26.0k5.0k8.0k14.0k7.0k19.0k12.0k4.0k6.0k5.0k6.0k6.0k6.0k17.0k3.0k22.0k22.0k29.0k51.0k72.0k90.0k109.0k149.0k204.0k194.0k111.0k23.0k3.0k

Pre tax profit

9.8m9.3m11.1m10.2m10.1m14.8m12.7m13.2m15.5m15.6m11.4m15.6m12.9m12.1m15.5m14.3m13.7m14.8m13.4m9.7m14.2m3.9m7.7m7.2m8.6m10.5m9.2m6.5m4.0m12.6m34.9m

Income tax expense

3.4m3.3m3.8m3.4m3.5m5.2m4.1m4.8m5.3m5.4m4.0m5.3m4.0m4.2m5.5m5.2m4.8m5.7m4.6m3.4m4.9m3.7m1.4m1.9m1.8m2.4m2.2m1.4m1.2m3.3m7.4m

Net Income

6.4m6.0m7.3m6.8m6.6m9.6m8.6m8.5m10.2m10.2m7.4m10.3m8.8m7.9m10.1m9.1m8.9m9.1m8.8m6.3m9.3m240.0k6.3m5.3m6.8m8.1m7.1m5.1m2.8m9.4m27.5m

Meridian Bioscience Balance Sheet

Quarterly

USDQ3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

58.2m41.5m28.4m25.6m26.2m24.3m27.9m33.1m38.6m40.4m43.7m38.2m39.3m49.5m42.7m46.0m53.4m48.9m45.8m49.3m54.7m55.3m54.7m56.4m57.9m61.5m66.1m55.2m68.6m49.6m63.4m

Accounts Receivable

18.5m20.3m25.4m24.0m24.0m27.8m24.3m23.8m23.7m25.2m22.5m26.8m25.8m23.6m30.3m28.0m27.6m32.5m31.3m24.3m27.0m27.7m32.1m33.8m28.9m31.8m33.0m32.0m35.3m40.2m42.4m

Prepaid Expenses

4.6m2.7m5.5m6.6m2.4m5.0m5.1m3.1m5.4m4.8m3.1m6.5m6.4m3.2m6.5m6.4m3.4m4.9m6.4m7.8m4.7m5.3m6.1m5.5m8.3m4.4m4.7m6.9m5.7m5.8m7.9m

Inventories

26.8m28.7m32.2m34.1m33.7m32.1m33.1m30.3m32.4m34.3m37.7m38.1m37.6m34.4m33.0m33.6m38.8m41.9m43.4m44.7m42.4m40.9m43.6m43.8m45.2m41.9m40.9m43.3m42.8m41.0m60.5m

Current Assets

110.1m95.2m93.8m92.5m89.4m92.2m93.8m93.3m103.1m108.6m111.2m114.0m113.5m114.7m116.5m118.0m123.2m128.2m126.9m126.0m128.8m129.2m136.6m139.5m140.2m139.6m144.7m137.4m152.4m136.6m174.2m

PP&E

21.7m24.4m24.8m26.5m26.6m26.6m26.5m25.8m25.9m25.8m26.1m26.9m27.3m27.9m28.0m27.4m27.4m30.2m30.1m30.4m30.2m30.2m30.4m30.3m30.5m30.9m30.8m31.8m30.5m30.4m30.8m

Goodwill

9.9m22.8m23.5m23.4m22.7m23.1m22.8m23.1m22.4m22.4m23.4m23.5m23.8m22.6m22.1m22.8m22.1m64.5m63.7m60.7m60.8m54.6m55.0m55.4m54.8m54.4m54.6m90.1m90.0m89.2m118.6m

Total Assets

149.3m156.2m157.2m158.0m155.2m158.3m158.8m157.3m166.0m171.0m174.9m178.2m178.8m177.4m178.3m179.3m186.4m258.4m254.9m250.1m251.9m245.1m252.0m254.5m254.0m249.9m254.0m322.4m338.1m319.1m419.8m

Accounts Payable

3.3m5.2m5.7m6.1m6.2m5.5m6.2m5.5m5.8m6.2m5.0m7.8m6.4m5.9m6.1m5.5m7.2m7.9m7.4m7.5m6.4m5.9m8.5m7.6m7.4m6.2m7.8m8.4m7.9m7.9m13.5m

Short-term debt

16.1m16.9m17.5m18.1m19.0m19.5m20.0m3.0m3.4m4.1m4.5m4.5m4.5m4.5m4.9m5.6m6.0m1.5m1.8m

Current Liabilities

11.9m17.5m17.0m17.2m16.6m16.3m17.5m19.0m17.6m19.7m17.5m17.8m16.9m14.5m15.2m13.3m15.7m21.3m20.2m21.0m19.9m20.0m23.5m25.8m24.5m20.7m24.1m19.8m34.9m37.9m43.5m

Long-term debt

56.8m55.7m53.5m52.4m51.3m49.0m47.9m46.4m43.4m41.9m75.8m80.3m52.9m103.7m

Non-Current Liabilities

2.0m2.0m2.1m2.1m67.2m65.8m63.3m61.2m57.6m55.6m54.4m54.4m50.5m48.2m114.1m106.0m76.7m143.0m

Total Debt

16.1m16.9m17.5m18.1m19.0m19.5m20.0m59.8m59.1m57.6m56.9m55.8m53.5m52.4m51.3m49.1m47.9m75.8m80.3m54.5m105.5m

Common Stock

41.0m41.0m41.2m41.3m41.3m41.4m41.5m41.5m

Preferred Stock

Additional Paid-in Capital

93.7m96.0m96.4m97.6m101.1m101.5m102.0m104.9m105.9m106.4m109.5m110.1m110.7m113.5m114.1m114.8m120.2m121.3m121.7m124.2m124.7m125.2m127.4m127.6m128.7m130.9m132.0m132.3m133.6m134.6m135.6m

Retained Earnings

44.6m40.5m40.0m39.1m36.8m38.7m39.4m33.0m43.3m45.6m46.4m48.4m49.0m48.4m50.2m50.9m51.5m52.2m52.6m47.5m51.5m46.5m47.9m47.9m49.5m52.3m54.1m59.0m65.9m75.3m102.8m

Total Equity

137.4m136.6m137.6m138.1m137.7m140.8m141.0m138.3m148.4m151.3m157.4m160.3m161.8m160.8m161.1m163.9m168.6m169.8m168.9m165.7m170.8m167.5m172.9m174.3m175.1m178.6m181.6m188.6m197.3m204.5m233.3m

Debt to Equity Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.4 x0.4 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.4 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.5 x1.5 x1.5 x1.5 x1.5 x1.5 x1.5 x1.5 x1.4 x1.4 x1.7 x1.7 x1.6 x1.8 x

Meridian Bioscience Cash Flow

Quarterly

USDQ3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

6.4m6.0m13.3m20.1m6.6m16.2m24.8m8.5m18.7m28.9m7.4m17.7m26.6m7.9m18.0m27.1m8.9m18.0m26.7m6.3m15.6m15.8m6.3m11.6m18.4m8.1m15.2m20.3m2.8m12.2m39.7m

Depreciation and Amortization

845.0k1.7m2.5m903.0k1.8m2.7m815.0k1.7m2.5m1.4m2.8m4.2m1.4m2.7m3.9m1.3m2.5m4.7m2.0m4.1m6.1m2.1m4.1m6.1m2.1m4.2m6.8m2.9m5.9m9.4m

Accounts Receivable

(3.0m)(4.2m)(52.0k)317.0k(951.0k)1.0m550.0k(4.9m)(6.4m)

Inventories

(2.4m)(2.4m)(4.1m)(37.0k)832.0k(67.0k)(3.5m)(2.5m)(17.8m)

Accounts Payable

1.3m3.7m3.0m(4.1m)(1.3m)(1.7m)(664.0k)1.6m4.4m

Cash From Operating Activities

13.6m10.3m16.6m12.5m18.9m31.9m16.0m22.4m32.5m9.3m13.6m23.6m16.1m20.0m31.2m12.1m18.5m26.0m13.0m25.1m32.5m5.2m13.8m23.6m9.4m21.0m28.3m5.3m15.7m31.7m

Purchases of PP&E

(2.6m)(5.3m)(7.7m)(1.1m)(1.8m)(3.0m)(403.0k)(1.4m)(2.2m)(899.0k)(2.6m)(4.0m)(1.3m)(2.6m)(3.8m)(776.0k)(1.5m)(2.7m)(1.4m)(2.3m)(3.4m)(1.2m)(2.2m)(3.3m)(1.1m)(2.1m)(3.3m)(340.0k)(1.5m)(2.5m)

Cash From Investing Activities

(2.6m)(5.3m)(7.7m)(1.9m)(2.8m)(3.9m)(403.0k)(1.4m)(2.2m)(2.5m)(4.2m)(5.7m)(1.3m)(2.6m)(2.6m)(1.4m)(64.3m)(65.4m)(1.4m)(2.3m)(3.4m)(1.2m)(2.2m)(3.3m)(1.1m)(2.1m)(48.6m)(340.0k)(1.5m)(53.8m)

Short-term Borrowings

(27.0m)(27.0m)

Long-term Borrowings

(750.0k)(750.0k)(1.5m)(2.6m)(1.1m)(2.2m)(3.4m)(1.1m)(2.2m)(50.2m)

Dividends Paid

(7.7m)(15.5m)(23.2m)(7.8m)(15.6m)(23.4m)(15.7m)(15.7m)(23.5m)(7.9m)(16.2m)(24.5m)(8.3m)(16.7m)(25.0m)(8.4m)(16.8m)(25.2m)(8.4m)(13.7m)(19.0m)(5.3m)(10.6m)(15.9m)(5.3m)(10.6m)(10.6m)

Cash From Financing Activities

(7.0m)(14.6m)(21.7m)(7.5m)(15.4m)(23.0m)(14.3m)(13.6m)(21.4m)(7.5m)(15.6m)(23.8m)(7.8m)(16.0m)(24.4m)(6.9m)45.0m35.9m(8.9m)(14.9m)(21.3m)(6.4m)(12.8m)(19.1m)(6.3m)(12.3m)15.1m(27.1m)22.9m

Net Change in Cash

3.6m(9.5m)(12.3m)2.6m711.0k4.3m1.6m7.0m8.8m(553.0k)(6.1m)(5.0m)6.5m(328.0k)2.9m3.4m(1.0m)(4.2m)2.1m7.5m8.0m(2.4m)(672.0k)858.0k1.8m6.3m(5.6m)6.2m(12.8m)1.0m

Meridian Bioscience Ratios

USDQ3, 2010

Financial Leverage

1.1 x

Meridian Bioscience Employee Rating

2.256 votes
Culture & Values
2.2
Work/Life Balance
2.7
Senior Management
2
Salary & Benefits
2.5
Career Opportunities
2.3
Source